These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35615355)

  • 1. Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs.
    Garantziotis P; Nikolakis D; Doumas S; Frangou E; Sentis G; Filia A; Fanouriakis A; Bertsias G; Boumpas DT
    Front Immunol; 2022; 13():860726. PubMed ID: 35615355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications.
    Hubbard EL; Bachali P; Kingsmore KM; He Y; Catalina MD; Grammer AC; Lipsky PE
    Genome Med; 2023 Oct; 15(1):84. PubMed ID: 37845772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression.
    Toro-Domínguez D; Martorell-Marugán J; Goldman D; Petri M; Carmona-Sáez P; Alarcón-Riquelme ME
    Arthritis Rheumatol; 2018 Dec; 70(12):2025-2035. PubMed ID: 29938934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and stratification of systemic lupus erythematosus patients into two transcriptionally distinct clusters based on IFN-I signature.
    Shobha V; Mohan A; Malini AV; Chopra P; Karunanithi P; Subramani Thulasingam S; Selvam S; Deyati A; Srivastava R; Basavanthappa S; Lemos N; Sunitha SM; Mazumder Tagore D; Anand A; Pant S; Jayaswal V; Ramarao M; Dudhgaonkar S
    Lupus; 2021 Apr; 30(5):762-774. PubMed ID: 33497307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratification of Patients With Sjögren's Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic Implications.
    Martin-Gutierrez L; Peng J; Thompson NL; Robinson GA; Naja M; Peckham H; Wu W; J'bari H; Ahwireng N; Waddington KE; Bradford CM; Varnier G; Gandhi A; Radmore R; Gupta V; Isenberg DA; Jury EC; Ciurtin C
    Arthritis Rheumatol; 2021 Sep; 73(9):1626-1637. PubMed ID: 33645922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores.
    Speyer CB; Li D; Guan H; Yoshida K; Stevens E; Jorge AM; Everett BM; Feldman CH; Costenbader KH
    Rheumatol Int; 2020 Feb; 40(2):257-261. PubMed ID: 31784790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.
    Lewandowski LB; Schanberg LE; Thielman N; Phuti A; Kalla AA; Okpechi I; Nourse P; Gajjar P; Faller G; Ambaram P; Reuter H; Spittal G; Scott C
    Lupus; 2017 Feb; 26(2):186-194. PubMed ID: 27488473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeine intake influences disease activity and clinical phenotype in systemic lupus erythematosus patients.
    Orefice V; Ceccarelli F; Barbati C; Lucchetti R; Olivieri G; Cipriano E; Natalucci F; Perricone C; Spinelli FR; Alessandri C; Valesini G; Conti F
    Lupus; 2020 Oct; 29(11):1377-1384. PubMed ID: 32703116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cluster of type II interferon-regulated genes associates with disease activity in patients with systemic lupus erythematosus.
    Siddiqi KZ; Zinglersen AH; Iversen KK; Rasmussen NS; Nielsen CT; Jacobsen S
    J Autoimmun; 2022 Oct; 132():102869. PubMed ID: 35933792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Reported Physical Activity Is Associated with Lupus Nephritis in Systemic Lupus Erythematosus: Data from KORean Lupus Network (KORNET) Registry.
    Kim SK; Choe JY; Lee SS
    Yonsei Med J; 2018 Sep; 59(7):857-864. PubMed ID: 30091319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
    Duroux-Richard I; Cuenca J; Ponsolles C; Piñeiro AB; Gonzalez F; Roubert C; Areny R; Chea R; Pefaur J; Pers YM; Figueroa FE; Jorgensen C; Khoury M; Apparailly F
    Int J Mol Sci; 2015 Jul; 16(8):16953-65. PubMed ID: 26225955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD14 (C-159T) polymorphism is associated with increased susceptibility to SLE, and plasma levels of soluble CD14 is a novel biomarker of disease activity: A hospital-based case-control study.
    Panda AK; Tripathy R; Das BK
    Lupus; 2021 Feb; 30(2):219-227. PubMed ID: 33176568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers.
    Chasset F; Ribi C; Trendelenburg M; Huynh-Do U; Roux-Lombard P; Courvoisier DS; Chizzolini C;
    Rheumatology (Oxford); 2020 Nov; 59(11):3468-3478. PubMed ID: 32375176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 is involved in the pathogenesis of system lupus erythematosus through promoting pathogenic antibody production.
    Zhang M; Yao C; Cai J; Liu S; Liu XN; Chen Y; Wang S; Ji P; Pan M; Kang Z; Wang Y
    J Transl Med; 2019 Jan; 17(1):37. PubMed ID: 30670047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Dolff S; Wilde B; Patschan S; Dürig J; Specker C; Philipp T; Kribben A; Witzke O
    Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus.
    Smith MA; Henault J; Karnell JL; Parker ML; Riggs JM; Sinibaldi D; Taylor DK; Ettinger R; Grant EP; Sanjuan MA; Kolbeck R; Petri MA; Casey KA
    Sci Rep; 2019 Oct; 9(1):14433. PubMed ID: 31594956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
    Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM
    Front Immunol; 2019; 10():2512. PubMed ID: 31708928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.